• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tempest Therapeutics Inc (NQ: TPST )

    1.330 -0.070 (-5.00%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 254,193
    Open 1.420
    Bid (Size) 1.300 (10)
    Ask (Size) 1.370 (100)
    Prev. Close 1.400
    Today's Range 1.320 - 1.420
    52wk Range 0.1700 - 9.770
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
    Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study 
    From Tempest Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -69.84%
    -69.84%
    1 Month
    +12.71%
    +12.71%
    3 Month
    -37.26%
    -37.26%
    6 Month
    -73.87%
    -73.87%
    1 Year
    +331.82%
    +331.82%

    More News

    Read More
    Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
    From Tempest Therapeutics
    Via GlobeNewswire
    Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
    Via Benzinga
    Exposures Product Safety
    Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
    From Tempest Therapeutics
    Via GlobeNewswire
    TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    $55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
    Via Benzinga
    Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Gold Rises 1%; Accenture Shares Surge After Q3 Results
    Via Benzinga
    What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
    Via Benzinga
    Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
    Via InvestorPlace
    Why Is Avrobio (AVRO) Stock Moving Today?
    Via InvestorPlace
    Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
    From Tempest Therapeutics
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.